Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
15
12
2021
accepted:
14
04
2022
revised:
13
04
2022
pubmed:
3
5
2022
medline:
2
12
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
The retina shares structural and functional similarities with the brain. Furthermore, structural changes in the retina have been observed in patients with schizophrenia spectrum disorders (SSDs). This systematic review and meta-analysis investigated retinal abnormalities and their association with clinical factors for SSD. Studies related to retinal layers in SSD patients were retrieved from PubMed, Scopus, Web of Science, Cochrane Controlled Register of Trials, International Clinical Trials Registry Platform, and PSYNDEX databases from inception to March 31, 2021. We screened and assessed the eligibility of the identified studies. EZR ver.1.54 and the metafor package in R were used for the meta-analysis and a random-effects or fixed-effects model was used to report standardized mean differences (SMDs). Twenty-three studies (2079 eyes of patients and 1571 eyes of controls) were included in the systematic review and meta-analysis. The average peripapillary retinal nerve fiber layer (pRNFL) thickness, average macular thickness (MT), and macular ganglion cell layer-inner plexiform layer (GCL-IPL) thickness were significantly lower in patients than in controls (n = 14, 6, and 3, respectively; SMD = -0.33, -0.49, and -0.43, respectively). Patients also had significantly reduced macular volume (MV) compared to controls (n = 7; SMD = -0.53). The optic cup volume (OCV) was significantly larger in patients than in controls (n = 3; SMD = 0.28). The meta-regression analysis indicated an association between several clinical factors, such as duration of illness and the effect size of the pRNFL, macular GCL-IPL, MT, and MV. Thinning of the pRNFL, macular GCL-IPL, MT, and MV and enlargement of the OCV in SSD were observed. Retinal abnormalities may be applicable as state/trait markers in SSDs. The accumulated evidence was mainly cross-sectional and requires verification by longitudinal studies to characterize the relationship between OCT findings and clinical factors.
Identifiants
pubmed: 35501407
doi: 10.1038/s41380-022-01591-x
pii: 10.1038/s41380-022-01591-x
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3592-3616Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77:201–10.
pubmed: 31664453
Kraguljac NV, McDonald WM, Widge AS, Rodriguez CI, Tohen M, Nemeroff CB. Neuroimaging biomarkers in schizophrenia. Am J Psychiatry. 2021;178:509–21.
pubmed: 33397140
pmcid: 8222104
Davison J, O’Gorman A, Brennan L, Cotter DR. A systematic review of metabolite biomarkers of schizophrenia. Schizophr Res. 2018;195:32–50.
pubmed: 28947341
Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999;46:729–39.
pubmed: 10494440
Kochunov P, Hong LE. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. Schizophr Bull. 2014;40:721–8.
pubmed: 24870447
pmcid: 4059450
Ashe PC, Berry MD, Boulton AA. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:691–707.
pubmed: 11383973
Komatsu H, Takeuchi H, Kikuchi Y, Ono C, Yu Z, Iizuka K, et al. Ethnicity-dependent effects of schizophrenia risk variants of the OLIG2 gene on OLIG2 transcription and white matter integrity. Schizophr Bull. 2020;46:1619–28.
pubmed: 32285113
pmcid: 7846078
Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Lee C-U, Ciszewski AA, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry. 2003;160:156–64.
pubmed: 12505815
pmcid: 2845847
Pantelis C, Velakoulis D, Wood SJ, Yücel M, Yung AR, Phillips LJ, et al. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies. Int Rev Psychiatry. 2007;19:371–81.
pubmed: 17671870
Sato Y, Sakuma A, Ohmuro N, Katsura M, Abe K, Tomimoto K, et al. Relationship between white matter microstructure and hallucination severity in the early stages of psychosis: a diffusion tensor imaging study. Schizophrenia Bulletin Open 2021;2:sgab015.
van Erp TGM, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21:547–53.
pubmed: 26033243
London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44–53.
pubmed: 23165340
García-Bermúdez MY, Freude KK, Mouhammad ZA, van Wijngaarden P, Martin KK, Kolko M. Glial cells in glaucoma: friends, foes, and potential therapeutic Targets. Front Neurol. 2021;12:624983.
pubmed: 33796062
pmcid: 8007906
Podoleanu AG. Optical coherence tomography. J Microsc. 2012;247:209–19.
pubmed: 22708800
pmcid: 3563006
Tsang SH, Sharma T. Optical coherence tomography. Adv Exp Med Biol. 2018;1085:11–13.
pubmed: 30578476
Samani NN, Proudlock FA, Siram V, Suraweera C, Hutchinson C, Nelson CP, et al. Retinal layer abnormalities as biomarkers of schizophrenia. Schizophr Bull. 2018;44:876–85.
pubmed: 29272501
Mutlu U, Bonnemaijer PWM, Ikram MA, Colijn JM, Cremers LGM, Buitendijk GHS, et al. Retinal neurodegeneration and brain MRI markers: the Rotterdam Study. Neurobiol Aging. 2017;60:183–91.
pubmed: 28974335
Bannai D, Lizano P, Kasetty M, Lutz O, Zeng V, Sarvode S, et al. Retinal layer abnormalities and their association with clinical and brain measures in psychotic disorders: a preliminary study. Psychiatry Res Neuroimaging. 2020;299:111061.
pubmed: 32145500
pmcid: 7183910
Ascaso FJ, Cabezón L, Quintanilla MA, Galve LG, López-Antón R, Cristóbal JA, et al. Retinal nerve fiber layer thickness measured by optical coherence tomography in patients with schizophrenia: a short report. Eur J Psychiatry. 2010;24:227–35.
Lee WW, Tajunisah I, Sharmilla K, Peyman M, Subrayan V. Retinal nerve fiber layer structure abnormalities in schizophrenia and its relationship to disease state: evidence from optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:7785–92.
pubmed: 24135757
Ascaso FJ, Rodriguez-Jimenez R, Cabezón L, López-Antón R, Santabárbara J, De la Cámara C, et al. Retinal nerve fiber layer and macular thickness in patients with schizophrenia: Influence of recent illness episodes. Psychiatry Res. 2015;229:230–6.
pubmed: 26213374
Yılmaz U, Küçük E, Ülgen A, Özköse A, Demircan S, Ulusoy DM, et al. Retinal nerve fiber layer and macular thickness measurement in patients with schizophrenia. Eur J Ophthalmol. 2016;26:375–8.
pubmed: 26742871
Mota M, Pêgo P, Klut C, Coutinho I, Santos C, Pires G, et al. Evaluation of structural changes in the retina of patients with schizophrenia. Ophthalmol Res: Int J. 2015;4:45–52.
Silverstein SM, Paterno D, Cherneski L, Green S. Optical coherence tomography indices of structural retinal pathology in schizophrenia. Psychol Med. 2018;48:2023–33.
pubmed: 29233210
Jerotic S, Lalovic N, Pejovic S, Mihaljevic M, Pavlovic Z, Britvic D, et al. Sex differences in macular thickness of the retina in patients with psychosis spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021;110:110280.
pubmed: 33567332
Celik M, Kalenderoglu A, Sevgi Karadag A, Bekir Egilmez O, Han-Almis B, Şimşek A. Decreases in ganglion cell layer and inner plexiform layer volumes correlate better with disease severity in schizophrenia patients than retinal nerve fiber layer thickness: findings from spectral optic coherence tomography. Eur Psychiatry. 2016;32:9–15.
pubmed: 26800301
Zhuo C, Ji F, Xiao B, Lin X, Chen C, Jiang D, et al. Antipsychotic agent-induced deterioration of the visual system in first-episode untreated patients with schizophrenia maybe self-limited: findings from a secondary small sample follow-up study based on a pilot follow-up study. Psychiatry Res. 2020;286:112906.
pubmed: 32151847
Zhuo C, Xiao B, Chen C, Jiang D, Li G, Ma X, et al. Abberant inverted U-shaped brain pattern and trait-related retinal impairment in schizophrenia patients with combined auditory and visual hallucinations: a pilot study. Brain Imaging Behav. 2021;15:738–47.
pubmed: 32304019
Kurtulmus A, Elbay A, Parlakkaya FB, Kilicarslan T, Ozdemir MH, Kirpinar I. An investigation of retinal layer thicknesses in unaffected first-degree relatives of schizophrenia patients. Schizophr Res. 2020;218:255–61.
pubmed: 31948898
Pan J, Zhou Y, Xiang Y, Yu J. Retinal nerve fiber layer thickness changes in schizophrenia: a meta-analysis of case-control studies. Psychiatry Res. 2018;270:786–91.
pubmed: 30551326
Lizano P, Bannai D, Lutz O, Kim LA, Miller J, Keshavan M. A meta-analysis of retinal cytoarchitectural abnormalities in schizophrenia and bipolar disorder. Schizophr Bull. 2020;46:43–53.
pubmed: 31112601
Kazakos CT, Karageorgiou V. Retinal changes in schizophrenia: a systematic review and meta-analysis based on individual participant data. Schizophr Bull. 2020;46:27–42.
pubmed: 31626695
Altun IK, Turedi N, Aras N, Atagun MI. Psychopharmacological signatures in the retina in schizophrenia and bipolar disorder: an optic coherence tomography study. Psychiatr Danub. 2020;32:351–8.
pubmed: 33370732
Liu Y, Huang L, Tong Y, Chen J, Gao D, Yang F. Association of retinal nerve fiber abnormalities with serum CNTF and cognitive functions in schizophrenia patients. PeerJ. 2020;8:e9279.
pubmed: 32676219
pmcid: 7335503
Budakoglu O, Ozdemir K, Safak Y, Sen E, Taskale B. Retinal nerve fibre layer and peripapillary vascular density by optical coherence tomography angiography in schizophrenia. Clin Exp Optom. 2021;104:788–94.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
Farsad-Naeimi A, Asjodi F, Omidian M, Askari M, Nouri M, Pizarro AB, et al. Sugar consumption, sugar sweetened beverages and Attention Deficit Hyperactivity Disorder: a systematic review and meta-analysis. Complementary Therapies Med. 2020;53:102512.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
pubmed: 20652370
Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408–14.
pubmed: 23337781
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
pubmed: 18436948
pmcid: 2335261
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
pubmed: 23208313
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557.
pubmed: 12958120
pmcid: 192859
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.
pubmed: 16807131
Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1:112–25.
pubmed: 26061377
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 470-461
pubmed: 9492685
pmcid: 2665578
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
pubmed: 9310563
pmcid: 2127453
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
pubmed: 10877304
Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. AHRQ methods for effective health care conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
pubmed: 3616518
Grzybowski A, Barboni P. OCT in central nervous system diseases: the eye as a window to the brain. Springer International Publishing; 2016. p. 1–342. https://doi.org/10.1007/978-3-319-24085-5 .
Grzybowski A, Barboni P. OCT and imaging in central nervous system diseases: the eye as a window to the brain. 2nd ed. Springer International Publishing; 2020. p. 1–561. https://doi.org/10.1007/978-3-030-26269-3 .
Tan CS, Lim LW, Ting DS. Assessment of choroidal and retinal thickness in psychosis. Psychiatry Res. 2018;270:1172.
pubmed: 29885780
Silverstein SM. Issues in the aggregation of data on retinal structure and function in schizophrenia. Schizophr Bull. 2020;46:15–16.
pubmed: 31747013
Silić A, Ostojić D, Karlović D. ERG and OCT as an effective screening and staging tools for schizophrenia? Psychiatr Danub. 2020;32:74–75.
pubmed: 32303034
Mentek M, Aptel F, Godin-Ribuot D, Tamisier R, Pepin JL, Chiquet C. Response to letter to editor “Optical coherence tomography (OCT) findings in obstructive sleep apnea” by Piotr Kanclerz. Sleep Med Rev. 2018;42:232–3.
pubmed: 30274745
Malaspina D, Butler PD. A vision for psychosis research: Commentary on “New insights into schizophrenia: a look at the eye and related structures”. Psychiatr Danubina. 2020;32:70–71.
Kurtulmus A, Elbay A, Ozdemir MH. Response to commentary “Retinal nerve fiber layer analysis in unaffected first-degree relatives of schizophrenia patients”. Schizophr Res. 2020;220:273–4.
pubmed: 32317222
Kéri S. The contribution of retinal dysfunctions to visual impairments in schizophrenia. Psychiatr Danub. 2020;32:76–77.
pubmed: 32303035
Ferro Desideri L, Vagge A, Nicolò M, Traverso CE. Retinal nerve fiber layer analysis in unaffected first-degree relatives of schizophrenia patients. Schizophr Res. 2020;220:289–90.
pubmed: 32199715
Bannai D, Lizano P. Identifying retinal layer endophenotypes for schizophrenia. Schizophr Res. 2020;220:25–26.
pubmed: 32247746
pmcid: 7306439
Ahmad M, Joe P, Malaspina D, Smith RT. Reply to comments on “A pilot study assessing retinal pathology in psychosis using optical coherence tomography: Choroidal and macular thickness”. Psychiatry Res. 2019;279:367.
pubmed: 29908783
Adhan I, Bannai D, Lizano P. Commentary: Can retinal imaging biomarkers inform psychosis pathophysiology? Schizophr Res. 2020;215:3–5.
pubmed: 31668491
Malaspina D. Looking schizophrenia in the eye. Am J Psychiatry. 2013;170:1382–4.
pubmed: 24306333
Maziade M, Silverstein SM. The place of the retina in psychiatry: uniting neurobiological and neurodevelopmental research with clinical research in psychiatric disorders. Schizophr Res. 2020;219:1–4.
pubmed: 32249123
Schönfeldt-Lecuona C, Schmidt A, Pinkhardt EH, Lauda F, Connemann BJ, Freudenmann RW, et al. [Optical coherence tomography (OCT)–a new diagnostic tool in psychiatry?]. Fortschr Neurol Psychiatr. 2014;82:566–71.
pubmed: 25299627
Hassenstein A. [Quo vadis neuroimaging? The eye as window to the brain. Current options and future perspectives]. Ophthalmologe. 2014;111:676–80.
pubmed: 25028070
Delıbaş DH, Karti Ö, Erdoğan E, Şahın T, Bılgıç Ö, Erol A. Decreases in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in schizophrenia, relation to insight: a controlled study. Anadolu Psikiyatr Derg. 2018;19:264–73.
Karadaǧ AS, Kalenderoǧlu A. Psychiatric disorders and eye: optical coherent tomography in psychiatry aspect. Klin Psikiyatr Derg. 2017;20:227–37.
Tan A, Schwitzer T, Conart JB, Angioi-Duprez K. Study of retinal structure and function in patients with major depressive disorder, bipolar disorder or schizophrenia: a review of the literature. J Fr Ophtalmol. 2020;43:e157–e166.
pubmed: 32381369
Silverstein SM, Rosen R. Schizophrenia and the eye. Schizophr Res Cogn. 2015;2:46–55.
pubmed: 26345525
pmcid: 4559409
Silverstein SM, Fradkin SI, Demmin DL. Schizophrenia and the retina: towards a 2020 perspective. Schizophr Res. 2020;219:84–94.
pubmed: 31708400
Schönfeldt-Lecuona C, Kregel T, Schmidt A, Pinkhardt EH, Lauda F, Kassubek J, et al. From imaging the brain to imaging the retina: optical coherence tomography (OCT) in schizophrenia. Schizophr Bull. 2016;42:9–14.
pubmed: 26048298
Nguyen CTO, Hui F, Charng J, Velaedan S, van Koeverden AK, Lim JKH, et al. Retinal biomarkers provide “insight” into cortical pharmacology and disease. Pharm Ther. 2017;175:151–77.
Jurišić D, Ćavar I, Sesar A, Sesar I, Vukojević J, Ćurković M. New insights into schizophrenia: a look at the eye and related structures. Psychiatr Danub. 2020;32:60–69.
pubmed: 32303031
Jerotic S, Ignjatovic Z, Silverstein SM, Maric NP. Structural imaging of the retina in psychosis spectrum disorders: current status and perspectives. Curr Opin Psychiatry. 2020;33:476–83.
pubmed: 32639357
Hosak L, Sery O, Sadykov E, Studnicka J. Retinal abnormatilites as a diagnostic or prognostic marker of schizophrenia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162:159–64.
pubmed: 29967563
Gracitelli CP, Abe RY, Diniz-Filho A, Vaz-de-Lima FB, Paranhos A Jr., Medeiros FA. Ophthalmology issues in schizophrenia. Curr Psychiatry Rep. 2015;17:28.
pubmed: 25773224
pmcid: 4523638
García-Portilla MP, García-Álvarez L, de la Fuente-Tomás L, Velasco-Iglesias Á, Sáiz PA, González-Blanco L, et al. Could structural changes in the retinal layers be a new biomarker of mental disorders? A systematic review and thematic synthesis. Rev Psiquiatr Salud Ment. 2019;12:116–29.
Duraković D, Silić A, Peitl V, Tadić R, Lončarić K, Glavina T, et al. The use of electroretinography and optical coherence tomography in patients with schizophrenia. Acta Clin Croat. 2020;59:729–39.
pubmed: 34285444
pmcid: 8253076
Cameron JR, Tatham AJ. A window to beyond the orbit: the value of optical coherence tomography in non-ocular disease. Acta Ophthalmologica. 2016;94:533–9.
pubmed: 26803923
Almonte MT, Capellàn P, Yap TE, Cordeiro MF. Retinal correlates of psychiatric disorders. Ther Adv Chronic Dis. 2020;11:2040622320905215.
pubmed: 32215197
pmcid: 7065291
Adams SA, Nasrallah HA. Multiple retinal anomalies in schizophrenia. Schizophr Res. 2018;195:3–12.
pubmed: 28755877
Joe P, Ahmad M, Riley G, Weissman J, Smith RT, Malaspina D. A pilot study assessing retinal pathology in psychosis using optical coherence tomography: choroidal and macular thickness. Psychiatry Res. 2018;263:158–61.
pubmed: 29567341
Zhuo C, Xiao B, Chen C, Jiang D, Li G, Ma X, et al. Antipsychotic agents deteriorate brain and retinal function in schizophrenia patients with combined auditory and visual hallucinations: s pilot study and secondary follow-up study. Brain Behav. 2020;10:e01611.
pubmed: 32285647
pmcid: 7303384
Chu EM, Kolappan M, Barnes TR, Joyce EM, Ron MA. A window into the brain: an in vivo study of the retina in schizophrenia using optical coherence tomography. Psychiatry Res. 2012;203:89–94.
pubmed: 22917503
pmcid: 4024658
Topcu-Yilmaz P, Aydin M, Cetin Ilhan B. Evaluation of retinal nerve fiber layer, macular, and choroidal thickness in schizophrenia: spectral optic coherence tomography findings. Psychiatry Clin Psychopharmacol. 2019;29:28–33.
Orum MH, Bulut M, Karadag AS, Dumlupinar E, Kalenderoglu A. Comparison of OCT findings of schizophrenia patients using FGA, clozapine, and SGA other than clozapine. Rev Psiquiatr Clin. 2020;47:165–75.
Zhuo C, Xiao B, Ji F, Lin X, Jiang D, Tian H, et al. Patients with first-episode untreated schizophrenia who experience concomitant visual disturbances and auditory hallucinations exhibit co-impairment of the brain and retinas-a pilot study. Brain Imaging Behav. 2020;15:1533–41.
Schönfeldt-Lecuona C, Kregel T, Schmidt A, Kassubek J, Dreyhaupt J, Freudenmann RW, et al. Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorder. Schizophr Res. 2020;219:5–12.
pubmed: 30981598
Miller M, Zemon V, Nolan-Kenney R, Balcer LJ, Goff DC, Worthington M, et al. Optical coherence tomography of the retina in schizophrenia: Inter-device agreement and relations with perceptual function. Schizophr Res. 2020;219:13–18.
pubmed: 31937481
Kozub KE, Shelepin IE, Chomskii AN, Sharybin EA, Ivanova EA. A structural and functional study of the retina in patients with schizophrenia. Oftalmol Zh. 2020;4:38–44.
Sarkar S, Rajalakshmi AR, Avudaiappan S, Eswaran S. Exploring the role of macular thickness as a potential early biomarker of neurodegeneration in acute schizophrenia. Int Ophthalmol. 2021;41:2737–46.
pubmed: 33856596
Jerotic S, Ristic I, Pejovic S, Mihaljevic M, Pavlovic Z, Britvic D, et al. Retinal structural abnormalities in young adults with psychosis spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;98:109825.
pubmed: 31759084
Zarei R, Anvari P, Eslami Y, Fakhraie G, Mohammadi M, Jamali A, et al. Retinal nerve fibre layer thickness is reduced in metabolic syndrome. Diabet Med. 2017;34:1061–6.
pubmed: 28430372
Yeung SC, You Y, Howe KL, Yan P. Choroidal thickness in patients with cardiovascular disease: a review. Surv Ophthalmol. 2020;65:473–86.
pubmed: 31923478
Salehi MA, Nowroozi A, Gouravani M, Mohammadi S, Arevalo JF. Associations of refractive errors and retinal changes measured by optical coherence tomography: a systematic review and meta-analysis. Surv Ophthalmol. 2021;67:591–607.
pubmed: 34343537
Mendoza-Santiesteban CE, Gabilondo I, Palma JA, Norcliffe-Kaufmann L, Kaufmann H. The retina in multiple system atrophy: systematic review and meta-analysis. Front Neurol. 2017;8:206.
pubmed: 28596752
pmcid: 5443142
La Morgia C, Di Vito L, Carelli V, Carbonelli M. Patterns of Retinal Ganglion Cell damage in neurodegenerative disorders: parvocellular vs. magnocellular degeneration in optical coherence tomography studies. Front Neurol. 2017;8:710.
pubmed: 29312131
pmcid: 5744067
Jahshan C, Wolf M, Karbi Y, Shamir E, Rassovsky Y. Probing the magnocellular and parvocellular visual pathways in facial emotion perception in schizophrenia. Psychiatry Res. 2017;253:38–42.
pubmed: 28342330
Bortolon C, Capdevielle D, Raffard S. Face recognition in schizophrenia disorder: a comprehensive review of behavioral, neuroimaging and neurophysiological studies. Neurosci Biobehav Rev. 2015;53:79–107.
pubmed: 25800172
Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108:17–40.
pubmed: 15104164
Appaji A, Nagendra B, Chako DM, Padmanabha A, Hiremath CV, Jacob A, et al. Retinal vascular abnormalities in schizophrenia and bipolar disorder: a window to the brain. Bipolar Disord. 2019;21:634–41.
pubmed: 31009139
Appaji A, Nagendra B, Chako DM, Padmanabha A, Jacob A, Hiremath CV, et al. Retinal vascular tortuosity in schizophrenia and bipolar disorder. Schizophr Res. 2019;212:26–32.
pubmed: 31466896
Appaji A, Nagendra B, Chako DM, Padmanabha A, Jacob A, Hiremath CV, et al. Examination of retinal vascular trajectory in schizophrenia and bipolar disorder. Psychiatry Clin Neurosci. 2019;73:738–44.
pubmed: 31400288
Appaji A, Nagendra B, Chako DM, Padmanabha A, Jacob A, Hiremath CV, et al. Relation between retinal vascular abnormalities and working memory impairment in patients with schizophrenia and bipolar disorder. Asian J Psychiatr. 2020;49:101942.
pubmed: 32070935
Demmin DL, Davis Q, Roché M, Silverstein SM. Electroretinographic anomalies in schizophrenia. J Abnorm Psychol. 2018;127:417–28.
pubmed: 29745706
Youssef P, Nath S, Chaimowitz GA, Prat SS. Electroretinography in psychiatry: a systematic literature review. Eur Psychiatry. 2019;62:97–106.
pubmed: 31553929
Dinkin M. Trans-synaptic retrograde degeneration in the human visual system: slow, silent, and real. Curr Neurol Neurosci Rep. 2017;17:16.
pubmed: 28229400
Onitsuka T, McCarley RW, Kuroki N, Dickey CC, Kubicki M, Demeo SS, et al. Occipital lobe gray matter volume in male patients with chronic schizophrenia: a quantitative MRI study. Schizophr Res. 2007;92:197–206.
pubmed: 17350226
pmcid: 2396445
Pergola G, Selvaggi P, Trizio S, Bertolino A, Blasi G. The role of the thalamus in schizophrenia from a neuroimaging perspective. Neurosci Biobehav Rev. 2015;54:57–75.
pubmed: 25616183
Denis P, Elena PP, Nordmann JP, Saraux H, Lapalus P. Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina. Neurosci Lett. 1990;116:81–86.
pubmed: 2147983
Stormann TM, Gdula DC, Weiner DM, Brann MR. Molecular cloning and expression of a dopamine D2 receptor from human retina. Mol Pharm. 1990;37:1–6.
Dong F, An JH, Ren YP, Yan DS, Zhou XT, Lü F, et al. [Expression of dopamine receptor D2 and adenosine receptor A2A in human retinal pigment epithelium]. Zhonghua Yan Ke Za Zhi. 2007;43:1110–3.
pubmed: 18331682
Dearry A, Falardeau P, Shores C, Caron MG. D2 dopamine receptors in the human retina: cloning of cDNA and localization of mRNA. Cell Mol Neurobiol. 1991;11:437–53.
pubmed: 1835903
Caravaggio F, Scifo E, Sibille EL, Hernandez-Da Mota SE, Gerretsen P, Remington G, et al. Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Exp Eye Res. 2018;175:32–41.
pubmed: 29883636
pmcid: 6167174
Alm A, Törnquist P. The uptake index method applied to studies on the blood-retinal barrier. I. A methodological study. Acta Physiol Scand. 1981;113:73–79.
pubmed: 7315440
Subhi Y, Forshaw T, Sørensen TL. Macular thickness and volume in the elderly: a systematic review. Ageing Res Rev. 2016;29:42–49.
pubmed: 27262495
Tourjman V, Kouassi É, Koué M-È, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, et al. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophrenia Res. 2013;151:43–47.
Munaut C, Lambert V, Noël A, Frankenne F, Deprez M, Foidart JM, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001;85:877–82.
pubmed: 11423466
pmcid: 1724050
Britze J, Pihl-Jensen G, Frederiksen JL. Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol. 2017;264:1837–53.
pubmed: 28567539
González-López JJ, Rebolleda G, Leal M, Oblanca N, Muñoz-Negrete FJ, Costa-Frossard L, et al. Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis. Biomed Res Int. 2014;2014:128517.
pubmed: 25313352
pmcid: 4182893
Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6:1.
pubmed: 31911624
pmcid: 6946650
Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231–40.
pubmed: 27605254
Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981–9.
pubmed: 28395674
Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res. 2018;268:114–22.
pubmed: 30015109
Üçok A, Çikrikçili U, Karabulut S, Salaj A, Öztürk M, Tabak Ö, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2015;30:290–5.
pubmed: 26163875
Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res. 2017;250:65–70.
pubmed: 28142068
Gao XR, Huang H, Kim H. Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort. Hum Mol Genet. 2019;28:1162–72.
pubmed: 30535121
Ly A, Banh J, Luu P, Huang J, Yapp M, Zangerl B. Interocular asymmetry of the superonasal retinal nerve fibre layer thickness and blood vessel diameter in healthy subjects. PLoS One. 2019;14:e0226728.
pubmed: 31869361
pmcid: 6927597
Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and continuity of schizophrenia and bipolar disorder: relation to biomarkers. Curr Pharm Des. 2020;26:191–200.
pubmed: 31840595
pmcid: 7403693